Medication Management on Hemodialysis Days
On hemodialysis days, you should hold dapagliflozin, diltiazem, and metoprolol tartrate. Continue cinacalcet and apixaban, but adjust apixaban timing based on dialysis schedule.
Specific Recommendations by Medication
Hold on HD Days:
Dapagliflozin - Hold on dialysis days. SGLT2 inhibitors should be discontinued when dialysis is initiated according to current evidence 1, 2. While the FDA removed the requirement to discontinue dapagliflozin at dialysis initiation based on safety data, there is no evidence of efficacy in patients receiving dialysis, and the mechanism of action (renal glucose excretion) becomes irrelevant 2.
Diltiazem - Hold on dialysis days due to hypotension risk. Non-dihydropyridine calcium channel blockers cause hypotension and should be avoided during dialysis sessions when patients are volume-depleted 3, 4. The risk of intradialytic hypotension is substantial, and the drug's hemodynamic effects are problematic during ultrafiltration.
Metoprolol Tartrate - Hold on dialysis days, particularly before dialysis. Beta-blockers cause hypotension and bradycardia, which are poorly tolerated during dialysis 3, 4, 5. However, if the patient has heart failure or coronary disease requiring beta-blockade, consider switching to a renally-eliminated agent like atenolol that can be dosed post-dialysis three times weekly 6, 7.
Continue with Timing Adjustments:
Apixaban - Continue but optimize timing. Apixaban exposure is significantly affected by dialysis timing 8. Give 2.5 mg immediately post-dialysis rather than pre-dialysis, as dialysis reduces drug exposure by approximately 48% when dosed pre-dialysis 8. Post-dialysis dosing ensures more consistent anticoagulation. The 2.5 mg dose post-dialysis provides similar exposure to 5 mg pre-dialysis 8. For high-risk procedures, apixaban should be held 48 hours before dialysis 9.
Cinacalcet - Continue on dialysis days without timing restrictions. Cinacalcet has high protein binding (93-97%) and is minimally removed by hemodialysis 10, 11. The drug can be administered regardless of dialysis timing, though some data suggest slightly higher clearance with hemodiafiltration 11. Standard dosing applies on dialysis days 12.
Key Clinical Pitfalls
Intradialytic hypotension: The combination of ultrafiltration with vasodilators (diltiazem) or negative inotropes (metoprolol) creates additive hypotensive effects that can compromise dialysis adequacy and patient safety 13, 6.
Apixaban timing errors: Giving apixaban pre-dialysis results in 48% lower drug exposure, potentially increasing thrombotic risk 8. Always dose post-dialysis.
Rebound hypertension: If holding antihypertensives, consider evening dosing of long-acting agents to control nocturnal blood pressure without causing intradialytic hypotension 6, 7.
Drug interactions: Diltiazem is a CYP3A4 inhibitor that increases apixaban levels by approximately 40% 3, 14. This combination increases bleeding risk and should be avoided if possible; consider switching to metoprolol if rate control is needed 14.
Alternative Strategies
For patients requiring continuous rate control or blood pressure management, consider renally-eliminated agents like lisinopril or atenolol that can be dosed three times weekly immediately post-dialysis, ensuring supervised administration and improved compliance 6, 7.